Advanced nodal disease associated with head and neck cancer warrants aggressive, often multi-modality therapy to maximize local-regional control. The expansion of a novel treatment paradigm developed by our institution includes the addition of a single-fraction of high dose spatially-fractionated radiation (GRID) to a conventional course of treatment.
Introduction
At the University of Kentucky, we have begun to routinely incorporate spatially fractionated radiation (GRID therapy) in the management of a variety of primaries presenting with sizeable (≥ 6 cm) malignant disease. One site with which we have growing experience is regional nodal disease associated with locally advanced head and neck primaries. Single GRID doses of ≥ 1500 cGy have been added to a conventionally fractionated (or altered fractionation) radiation schema for the purpose of facilitating neck dissection in the medically fit patient, or to improve odds of local-regional control in the inoperable patient. It has been feasible to dose-escalate the therapy plan for those patients who present with advanced neck Technology in Cancer Research & Treatment, Volume 5, Number 6, December 2006 tumors with minimal additional acute side effect and acceptable late toxicity. As a consequence, greater clinical objective and subjective response rates have been observed (1) (2) (3) (4) .
Background GRID therapy expands methods and principals of a technique developed some time ago. In the early part of the twentieth century, low energy (orthovoltage) x-ray was the only means of treating with radiotherapy. Skin dose was high due to poor tissue penetration by orthovoltage beams. Clinically, skin reactions were a common limiting factor for treatment of deep tumors. Techniques were developed to overcome skin tolerance while maintaining high tumor dose. One such technique known as spatial fraction involved the delivery of radiation through a block containing evenly-spaced open areas defined by a 'screen' or grid pattern (5) . In this way, only the small defined areas of tissue received high doses, while the adjacent blocked areas allowed for some 'skin sparing" and normal tissue regeneration. Clinical studies showed that skin and subcutaneous tissue could safely tolerate doses up to 20,000 cGy and differential doses of 6000-7000 cGy could thus be delivered to deep tumor (6). The technique was largely abandoned with advent of megavoltage equipment, which deposits maximum dose beneath the tissue surface thus earning its 'skin sparing' advantage. Recently however, spatial fractionation has been modified for use with megavoltage radiation equipment for treatment of large, bulky tumors that are otherwise poorly controlled by conventionally fractionated radiotherapy (7). Fractions nearly ten times greater than standard can be safely delivered to large tumors via single-fraction GRID technique. The beam properties and dosimetry for GRID therapy are specifically described elsewhere (1, 4, 7) .
To date, most of the clinical work involving spatially fractionated (GRID) therapy has been published regarding its use as a safe, palliative adjunct in patients with bulky tumors (4, 7). In fact, a higher clinical complete response is achieved when combining GRID therapy with conventional doses of radiation of 4,000 cGy or higher (7) . As such, we have expanded our treatment paradigm to include GRID therapy as part of the definitive treatment plan for patients in whom the presence of a large tumor jeopardizes local-regional control.
This study retrospectively reviews the results of use of a single GRID radiation dose added to a fractionated radiation treatment course for patients presenting with bulky or inoperable locally advanced neck disease at diagnosis. Treatment outcomes are presented. (Table I) Twenty-seven patients with previously untreated Stage IV (non-metastatic) head and neck primaries were treated with external beam radiation and GRID directed to neck disease (N2-N3) with curative intent at the University of Kentucky between July 1995 and December 2002. All patients had signed informed consent for GRID prior to treatment. Patient records were retrospectively reviewed. Medically suitable patients were treated with intent of primary organ preservation involving chemo-radiotherapy or radiation alone followed by planned neck dissection 4-6 weeks after completion of radiation.
Materials and Methods

Patient Characteristics and Clinical Staging
There were four female and 23 male patients whose median age was 65 (range 44-85 years). Histology in all but one patient was squamous cell carcinoma. Tumor and nodal classification was done as per 1997 AJCC clinical staging manual (8). Patient characteristics are listed in Table I . Primary sites of disease were as follows: 14 oropharynx; five oral cavity; five unknown primary; one nasopharynx; and one hypopharynx. One patient had synchronous primaries of both hypopharynx and oral cavity. Clinical nodal staging was as follows: [3] N2 and [24] N3. Median nodal tumor size was 7 cm (range 6-13 cm). Patients having bulky N2 necks were deemed eligible for GRID therapy in addition to definitive radiation if found medically inoperable.
Treatment
Aside from the GRID treatment, radiation was delivered using standard 3-field head and neck technique previously described elsewhere (9). In general, treatment was delivered using 6 MV or higher energy x-ray beam. Parallel opposed photon portals directed at upper neck were matched with a single anterior yoke portal to encompass the primary and the associated lymph node drainage areas. The spinal cord was limited to a maximum dose of 45 Gy after which electron fields were used to supplement the dose to the posterior cervical neck and/or as a part of a boost to tumor or node found overlying the cord. The majority, 20/27 (74%), of patients were treated with conventional (once a day) fractionation and the remainder by hyperfractionation (6/27) or accelerated fractionation with concomitant boost (1/27). Seven patients received concurrent chemotherapy.
Description of the GRID Technique
The GRID block is a 7 cm thick metal alloy (Cerrobend) structure that is physically fitted between two Lucite trays placed on the tray holder of a Varian 2100 C/D linear accelerator (Varian Oncology System, Palo Alto, CA). The physical block measures 16 × 16 cm 2 and contains 256 (7 mm) divergent holes evenly spaced to project a maximum field size of 20 × 20 cm 2 at isocenter. In this way, when placed in treatment position at a skin-to-source distance of 100 cm the block converts an open beam into a series of pencil-beams, producing a spatially fractionated treatment field; half of which is open and half of which is blocked (Fig. 1 ). The holes project 1 cm full-width-half-maximum beams at the isocenter of the machine with 1.8 cm center-to-center spacing. Dose distributions for treatment fields have been obtained. These indicate that the dose gradient across a treatment field matrix at approximately 1.5 cm depth in tissue (dmax) for a 6MV beam range from 15% to 40% of the total dose prescribed for blocked areas while nearly 100% of the total dose prescribed is delivered within the open areas (2, 7).
In all study patients, GRID therapy was delivered as a single fraction prescribed to dmax, either just prior to initiation of conventional therapy or shortly after conventional treatments were begun. No conventional treatment was given the day of GRID treatment. GRID treatment was delivered to encompass the nodal mass only, as determined by clinical and radiographic examinations. The field was directed off the spinal cord and mandible in all cases. If further field shaping was required, this was accomplished by placement of hand blocks placed atop the GRID block. GRID dose was 1500 cGy in all patients except one who received 2000 cGy.
Treatment Groups
For the purpose of this analysis patients were divided into two treatment groups designated as GRID + RT (Group 1; N=14) and GRID + RT + Surgery (Group 2; N=13).
In Group 1, median tumor diameter was 7 cm (range 6-10 cm). Eight patients were treated in planned definitive fashion, including the involved neck, which received median full dose of 70 Gy (range 68-79 Gy) plus GRID. The remaining patients received less than full dose to the involved neck; median 59 Gy (range 54-60 Gy) for the following reasons: four were to have undergone neck dissection but were either found to have progression of systemic disease [3] or were lost to follow-up [1] . One progressed at the primary site shortly thereafter of inter-current disease and died. One patient refused to continue radiation mid-treatment. All but two patients completed a full course of radiation to the primary.
In Group 2, median tumor diameter was 8 cm (range 6-13 cm). Fourteen patients received a median dose 59.4 Gy (range 54-72 Gy) plus GRID to the involved neck followed by a planned neck dissection. Primary tumor sites were taken to full dose in all but one patient whose primary was also resected at the time of planned neck dissection.
Statistical Methods
Patients were evaluated for local control of the involved neck, pathologic response, survival, and morbidity. All toxicities encountered during this study were evaluated according to the National Cancer Institute Common Toxicity Criteria.
Survival results including disease-free, median, and log rank p-values were obtained by Kaplain-Meier method and stepwise selection method by Cox regression in the LIFETEST and PHREG procedures in SAS x,y . The survival curves were also generated using the Kaplan-Meier method in the LIFETEST procedure (10, 12).
Results
GRID + RT (Group 1)
Follow-up ranged from 3 to 44 months (median = 10 months (Table II) at most recent active follow-up revealed the following: seven patients died of systemic disease, only one of whom sustained simultaneous regional neck recurrence (outside of the GRID treatment field) in addition to a new primary ten months following GRID. Four patients died of unrelated medical disease. Two patients were NED at 39 and 44 months from GRID. One patient was lost to follow-up after completion of radiation.
Acute treatment effects were limited to grades 2-3 skin reactions managed as an outpatient. There were no grade 4 toxicities. Late treatment effects (≥ 6 months posttreatment) seen within the GRID treatment field were evaluated in ten patients and limited to Grade 2 soft tissue and muscle fibrosis, which mildly restricted full neck mobility in two patients. Disease specific survival and local regional control for Group 1 was 50% and 86%, respectively, at 44 months follow-up ( Figure 2 ).
GRID + RT + Surgery (Group 2)
Follow-up ranged from 5 to 116 months (median = 38 months). Pathologic complete response rate (pCR) was 85% (N=11/13). Overall N3 neck control rate was 92% (12/13). Disease status at most recent follow-up for patients in Group 2 (Table III) is as follows: 62% (8/13) were NED (all of whom had achieved a pathologic complete response). Of the remainder, two had died of distant metastatic disease though had no local-regional recurrence. Three had died of intercurrent medical disease, one of whom had sustained local recurrence at the primary. Surgical toxicities were limited to three patients who experienced postoperative wound healing complications. One of these patients ultimately required debridement of flap necrosis, one required a flap closure due to wound breakdown; the other had delayed wound healing, successfully managed as an outpatient with no surgical intervention. Twelve patients were evaluable for late effects. There were four patients who demonstrated limitation of neck mobility due to fibrotic soft tissue changes. Overall survival for Group 2 was 62% (8/13). Disease specific survival and local regional control was 85% and 92%, respectively, at 116 months follow-up ( Figure 3 ).
Discussion
Local control and survival of advanced head and neck cancer have been negatively correlated with larger tumor volume (13-15). Radiobiologically, it is generally accepted that the larger the volume of disease, the greater the tumoricidal radiation dose required (16). Unfortunately, control of large bulky tumors by conventional external beam radiation is limited by normal surrounding tissue tolerance. Altered fractionation schemas have been developed as a means of maximizing tumor dose, sparing late effects of radiation on normal cells, and improving local control. Even so, overall local control by these methods remains challenging.
The most recent and largest randomized altered fractionation trial (RTOG) 90-03 reported 2-year local-regional control rates for stage III/IV non-metastatic head and neck cancer as 54% utilizing either hyperfractionation technique or accelerated fractionation with boost (17). By comparison, localregional control using conventional fractionation alone is 33-48% (18). Preoperative radiation followed by neck dissection for stage IIA-III disease affords local control rates of 68-91% (19). Similarly, by combining chemotherapy with altered fractionation, local control is reportedly as high as 70% at three years (20); however, toxicity can be significant and the rigorous nature of this treatment excludes all but those rare patients who have excellent performance status.
Of those patients in this study who received a full course of (definitive) therapy in addition to GRID (8/14), we found that they potentially achieved higher local control (88%) in the treated neck as compared to reported rates using conventional treatment alone. Admittedly numbers are small, nonetheless, these patients demonstrated excellent, often durable local control with limited toxicity.
Conventional radiation followed by planned neck dissection for N3 necks is associated with a pathologic complete response (pCR) rate of approximately 30-60% (18, 21); incidence falling steeply as nodal size increases beyond 6 cm (18). Not surprisingly, however, local control in those patients achieving a pCR is as high as 89-100% in contrast to 25-67% in those who experience less than a pCR (19) . When more aggressive means of treatment include combined chemo-radiation plus surgery, rates of pCR increase to as high as 78%, though not without increased toxicity (20) . Results for Group 2 indicate a pathologic complete response rate of 85% with an associated neck control rate of 92% comparing favorably to these reports. Evidence also suggests that the presence of pathologically positive lymph nodes negatively correlates with survival (22) (23) (24) . For those patients medi-cally fit enough to be treated by planned neck dissection, the addition of GRID treatment could theoretically lead to improved disease specific survival by improving pathologic response rates. Indeed, for those patients in Group 2 achieving pCR, median survival was 42 months, disease specific survival was 91% (only two patients who had pCR died of disease, while 8/11 survived or died of other cause).
Clearly, within the present neck staging system (AJCC) and based on our experience, patients for whom this technique is most appropriate are those with (bulky) N2-3 disease being treated definitively with RT or those with N3 disease being treated with combined surgery. Though we have found moderate clinical success in treating large tumor masses by adding GRID therapy to conventionally fractionated doses, we continue to explore and define the specific radiobiologic treatment effects induced by GRID. Intuitively, tumor should respond to treatment delivered via 'open' areas within the spatially defined GRID field with less response or perhaps even growth due to accelerated repopulation seen in adjacent 'blocked' areas. However, we have clinically observed uniform tumor regression throughout the treatment field suggesting that there are a host of indirect effects mediated by cellular cytokines: the basis of our on-going laboratory research. Radiobiologically, GRID therapy has been shown in laboratory studies to induce cytokines such as TNF-α and TGF-β1. Treatment related up-regulation of TNF-α has antiangiogenic properties associated with enhanced tumor cell kill. Between 24-72 hours following treatment, the TNF-α cytokine can be detected in blood serum of the patient. More interestingly, we have found that induction of TNF-α by GRID radiation can be correlated with complete clinical response by tumors. Its mechanism of action activates the apoptotic pathway in epithelial (tumor) cells as well as activating pathways, which increase ceramide production. Ceramide is a biological molecule implicated in the endothelial cell death (tumor vasculature) (25). Additionally, the down-regulation of TNF-β1 exerts a protective effect on normal tissues. The cytokine TGF-β1 (also measured in serum), decreases following GRID treatment. TGF-β1 is ordinarily associated with connective tissue scarring; thus, lowered serum levels may explain the absence of significant soft tissue toxicity seen clinically within a treatment field (26). Together, these cellular products may explain the therapeutic gain seen with GRID therapy.
Conclusion
This paper is the first we have reported to address the impact of GRID on a definitive treatment plan versus palliation only. It is also the first to examine the pathologic response of GRID and its subsequent impact on local-regional control. The data in this study suggest that GRID radiation can be safely incorporated into the definitive management of head and neck cancer presenting with advanced neck disease. Wound healing complications as a result of adding 15 Gy GRID radiotherapy to preoperative doses of conventionally fractionated radiation have been manageable and infrequent. Surgical techniques and feasibility have not been altered by the incorporation of GRID radiation, as might be expected. It is our hope that GRID therapy offers a treatment consideration for those patients demonstrating advanced neck disease (e.g., N2-3) who may be appropriate candidates for aggressive definitive non-surgical measures or for those demonstrating advanced neck disease (e.g., N3), for which neck dissection is a planned part of therapy.
